Page 1

ASX Announcement Quarterly Cash Flow Statement & Operational Highlights Recce Pharmaceuticals recce.com.au ACN 124 849 065 Highlights : • • • • • • Strong cash position of $ 22.92 million Topical Phase I / II burns study formalised with West Australian Health Department and Fiona Stanley Hospital Phase I ( I.V ) clinical study progressing at Adelaide's CMAX facility The PEW Charitable Trusts lists RECCE® 327 ( R327 ) on global register of non- traditional antibiotics in clinical development - only sepsis drug Encouraging Results from Anti - viral Screening Program Evaluating R327 Against SARS - COV - 2 Dual listed on Frankfurt Stock Exchange under code R9Q SYDNEY Australia , 27 April 2021 : Recce Pharmaceuticals Ltd ( ASX : RCE , FSE : R9Q ) , the Company developing New Classes of Synthetic Anti - infectives , today released its March 2021 quarter results and operational highlights . Financial Update The Company ended the quarter with a cash balance of $ 22.92 million . Net cash out- flows were ( $ 0.671 million ) , significantly offset by R & D rebates , grants and other state / federal initiatives . Research and Development ( $ 1.13m ) was the largest item of expenditure . Payments to related parties ( Executive & Director fees ) was ( $ 0.315m ) . In - flows of $ 963,488 ( part two of R & D rebate ( overseas ) - total to $ 1,566,030 for the year ending 30 June 2020 ) including grants and other initiatives . Overall , expenses were less than previous quarter with non - recurring costs for the Topical Phase I / II burns study completed and the West Australian Health Department sponsored study well - underway . ASX : RCE , FSE : R9Q Head Office : Level 25 , 88 Phillip Street , Aurora Place , SYDNEY NSW 2000 T +61 ( 02 ) 9256 2571 R & D Centre - Perth : Suite 10 , 3 Brodie Hall Drive , Technology Park , BENTLEY WA 6102 T +61 ( 8 ) 9362 9860 Washington Office : 1717 Pennsylvania Avenue NW , Suite 1025 , WASHINGTON DC 20006 USA